Imatinib
Sign in to save this workspacePrimary targets: BCR_ABL, ABL1, ABL2_ARG · FDA status: FDA Approved
Selectivity scorecard
KISS
99.00
Gini
0.718
CATDS
0.033
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Imatinib. Strongest target: PDGFRA at 98.9% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | PDGFRA | 98.9% | 1.1% |
| 2 | DDR1 | 94.5% | 5.5% |
| 3 | FMS | 92.2% | 7.8% |
| 4 | LCK | 90.2% | 9.8% |
| 5 | DDR2 | 87.7% | 12.3% |
| 6 | ABL1 | 86.2% | 13.8% |
| 7 | LYN | 80.6% | 19.4% |
| 8 | RAF1 | 74.0% | 26.0% |
| 9 | PDGFRB | 70.7% | 29.3% |
| 10 | ABL2_ARG | 63.1% | 36.9% |
| 11 | C_KIT | 62.1% | 37.9% |
| 12 | PDK2_PDHK2 | 43.2% | 56.8% |
| 13 | ARAF | 42.8% | 57.2% |
| 14 | BRAF | 39.8% | 60.2% |
| 15 | ROS_ROS1 | 39.8% | 60.3% |
| 16 | FGR | 38.9% | 61.1% |
| 17 | CAMKK2 | 38.6% | 61.4% |
| 18 | PKG2_PRKG2 | 31.0% | 69.0% |
| 19 | BLK | 30.4% | 69.6% |
| 20 | ERN1_IRE1 | 29.8% | 70.2% |
Selectivity landscape
Where Imatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Imatinib.
Atlas insights for Imatinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 1579.24 | |
| ALLOGRAFT_REJECTION | 4874.01 | |
| ANDROGEN_RESPONSE | 565.47 | |
| ANGIOGENESIS | 794.23 | |
| APICAL_JUNCTION | 5131.86 | |
| APICAL_SURFACE | 425.95 | |
| APOPTOSIS | 3665.05 | |
| BILE_ACID_METABOLISM | 308.46 | |
| CHOLESTEROL_HOMEOSTASIS | 764.16 | |
| COAGULATION | 576.33 | |
| COMPLEMENT | 2903.94 | |
| DNA_REPAIR | 862.62 | |
| E2F_TARGETS | 2208.38 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 1029.92 | |
| ESTROGEN_RESPONSE_EARLY | 1686.28 | |
| ESTROGEN_RESPONSE_LATE | 1497.37 | |
| FATTY_ACID_METABOLISM | 276.42 | |
| G2M_CHECKPOINT | 2309.36 | |
| GLYCOLYSIS | 1220.97 | |
| HEDGEHOG_SIGNALING | 421.26 | |
| HEME_METABOLISM | 1101.81 | |
| HYPOXIA | 1914.43 | |
| IL2_STAT5_SIGNALING | 1856.09 | |
| IL6_JAK_STAT3_SIGNALING | 2567.32 | |
| INFLAMMATORY_RESPONSE | 2680.56 | |
| INTERFERON_ALPHA_RESPONSE | 502.37 | |
| INTERFERON_GAMMA_RESPONSE | 3288.25 | |
| KRAS_SIGNALING_DN | 494.28 | |
| KRAS_SIGNALING_UP | 1970.45 | |
| MITOTIC_SPINDLE | 3648.46 | |
| MTORC1_SIGNALING | 1754.97 | |
| MYC_TARGETS_V1 | 1887.35 | |
| MYC_TARGETS_V2 | 474.52 | |
| MYOGENESIS | 1493.42 | |
| NOTCH_SIGNALING | 106.81 | |
| OXIDATIVE_PHOSPHORYLATION | 466.51 | |
| P53_PATHWAY | 2066.96 | |
| PANCREAS_BETA_CELLS | 159.02 | |
| PEROXISOME | 640.32 | |
| PI3K_AKT_MTOR_SIGNALING | 4445.30 | |
| PROTEIN_SECRETION | 821.51 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 325.84 | |
| SPERMATOGENESIS | 884.33 | |
| TGF_BETA_SIGNALING | 972.85 | |
| TNFA_SIGNALING_VIA_NFKB | 2493.37 | |
| UNFOLDED_PROTEIN_RESPONSE | 583.16 | |
| UV_RESPONSE_DN | 2500.64 | |
| UV_RESPONSE_UP | 1911.24 | |
| WNT_BETA_CATENIN_SIGNALING | 941.61 | |
| XENOBIOTIC_METABOLISM | 819.84 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.830 |
| SRR23303752 | — | 0.824 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.816 |
| aMVAC.P_005_TURBT_S223 | — | 0.812 |
| SRR10899984 | — | 0.810 |
Annotations
Sign in to read and post annotations.
Loading…